These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 10737489

  • 21. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK, Chervoneva I, Gomella LG.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1093-7. PubMed ID: 15001249
    [Abstract] [Full Text] [Related]

  • 22. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J, Pahernik S, Tremmel T, Haferkamp A, Buse S, Hohenfellner M.
    BJU Int; 2008 Nov 15; 102(10):1413-8. PubMed ID: 18537951
    [Abstract] [Full Text] [Related]

  • 23. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H, Lau W, Bergstralh E, Blute ML.
    J Urol; 2001 Dec 15; 166(6):2208-15. PubMed ID: 11696737
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.
    Urology; 2007 Jul 15; 70(1):106-10. PubMed ID: 17656218
    [Abstract] [Full Text] [Related]

  • 29. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
    Lowe BA, Lieberman SF.
    J Urol; 1997 Oct 15; 158(4):1452-6. PubMed ID: 9302141
    [Abstract] [Full Text] [Related]

  • 30. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database.
    Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR.
    J Urol; 1998 Oct 15; 160(4):1398-404. PubMed ID: 9751363
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Nov 15; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ, Kane CJ, Presti JC, Terris MK, Amling CL, Dorey F, Aronson WJ.
    J Urol; 2003 Mar 15; 169(3):969-73. PubMed ID: 12576824
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.